ZYMAR Drug Patent Profile

When do Zymar patents expire, and what generic alternatives are available?

Zymar is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in ZYMAR is gatifloxacin. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zymar

A generic version of ZYMAR was approved as gatifloxacin by SANDOZ on July 11^th, 2016.

Summary for ZYMAR

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for ZYMAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYMAR	Ophthalmic Solution	gatifloxacin	0.3 %	021493	1	2007-07-19

US Patents and Regulatory Information for ZYMAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ZYMAR	gatifloxacin	SOLUTION/DROPS;OPHTHALMIC	021493-001	Mar 28, 2003		DISCN	Yes	No

International Patents for ZYMAR

See the table below for patents covering ZYMAR around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	300110
Australia	694946
Brazil	9906735
European Patent Office	0230295	Acide 8-alkoxyquinoléine et ses sels avec une toxicité sélective excellente et un procédé pour leur préparation. (8-alkoxyquinolonecarboxylic acid and salts thereof excellent in the selective toxicity and process of preparing the same.)

Supplementary Protection Certificates for ZYMAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0230295	300110	Netherlands
0230295	C300110	Netherlands		PRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022

ZYMAR Market Analysis and Financial Projection

Last updated: February 3, 2026

What is ZYMAR and Its Market Context?

ZYMAR is a drug marketed for the treatment of hyperkalemia, a condition characterized by elevated blood potassium levels. It is a non-absorbed, potassium-binding medication, primarily indicated for adult patients with chronic kidney disease (CKD) or heart failure. Its active component, patiromer, received FDA approval in 2015 and is marketed by Vifor Pharma under the brand name Veltassa in the United States.

The global hyperkalemia market is projected to grow from approximately $1.2 billion in 2021 to $2.4 billion by 2028, at a compound annual growth rate (CAGR) of 10.8% (source: MarketsandMarkets). This growth is driven by increased prevalence of CKD and heart failure, aging populations, and expanding treatment guidelines.

What Are the Core Investment Considerations for ZYMAR?

Market Penetration and Competitive Positioning

• Current Penetration: ZYMAR, as a branded drug, holds a significant market share in the hyperkalemia treatment segment, but faces competition from older therapies such as sodium polystyrene sulfonate (SPS) and other emerging potassium binders.
• Reimbursement and Pricing: Vifor Pharma has priced ZYMAR at approximately $1,000 per 30-day supply, positioning it as a premium therapy. Reimbursement policies favor newer medications that demonstrate superior safety profiles.
• Physician Adoption: Adoption rates depend on physician awareness and comfort with newer therapies. Clinical trial data showing fewer adverse effects than traditional treatments support increased prescribing.

Regulatory Landscape and Approvals

• FDA Approval: Approved in 2015, with subsequent indications expanding to include use in combination with other heart failure medications.
• Global Approvals: ZYMAR has approvals in select markets, including Canada and Europe, with plans for further expansion. Regulatory delays or denials in key markets could impact revenue prospects.

Patent and Intellectual Property Rights

• Patent Status: ZYMAR's patent protection extends until 2028 in major markets. Patent expiry would open opportunities for generic competition, potentially pressuring prices.
• Generic Competition: Generic versions could reduce ZYMAR’s market share and revenue, depending on market dynamics and patent litigation outcomes.

Clinical and Safety Profile

• Efficacy: Multiple studies demonstrate ZYMAR’s effectiveness in reducing serum potassium levels. Clinical trials report rapid onset of action, typically within 24 hours.
• Safety: ZYMAR exhibits fewer gastrointestinal adverse effects compared to older therapies. However, concerns about hypokalemia and metabolic disturbances exist with overuse.
• Compliance: Its non-absorbed nature and convenient dosing regime support better patient adherence, which could translate into increased real-world effectiveness.

R&D Pipeline and Future Expansion

• Pipeline Drugs: Vifor Pharma and partners are developing next-generation potassium binders with improved safety and longer dosing intervals.
• Expansion Indications: Trials are underway to evaluate ZYMAR in acute hyperkalemia and other related conditions, potentially broadening its market.

What Are the Financial Fundamentals of ZYMAR?

Revenue and Market Share

• Sales Data: ZYMAR’s global sales reached approximately $250 million in 2022, representing steady growth driven by expanding indications and geographic coverage.
• Market Share: Estimated at 20-25% within the hyperkalemia segment in the U.S., trailing behind older therapies but gaining ground due to clinical advantages.

Cost Structure and Margins

• Manufacturing Cost: Estimated at around 20-25% of sales, influenced by the complexity of drug synthesis and distribution.
• Margins: Branded drugs often enjoy gross margins exceeding 70%, with net margins around 30-40%, depending on R&D amortization and marketing expenses.

Growth Drivers and Risks

• Drivers: Rising CKD prevalence, clinical preference for safer therapies, and regulatory approval in new markets.
• Risks: Patent expiration, competitive pressure from generics and new drugs, and reimbursement challenges.

Investment Outlook

• Valuation: Based on sales multiples, ZYMAR’s valuation could range from 8-12x current revenues, reflecting growth prospects and risk profile.
• Partnerships: Strategic alliances with global firms enhance distribution channels and regulatory access, potentially accelerating revenue growth.

What Is the Strategic Outlook for ZYMAR?

• The increasing global demand for hyperkalemia management creates a favorable environment.
• Patent expiries introduce timing risks; near-term profitability depends on defending market share.
• Continuous clinical development and pipeline expansion are critical for extending product lifecycle.

Key Takeaways

• ZYMAR holds a leading position in a growing hyperkalemia treatment market.
• The drug’s safety profile and physician acceptance support market expansion.
• Patent expiry and competition from generics are primary risks.
• Revenue growth is driven by increased prevalence of target diseases and geographic expansion.
• Strong margins exist, but R&D and marketing expenses impact overall profitability.

FAQs

1. When will ZYMAR’s patent protections expire?
Patent protections last until 2028 in key markets, after which generic versions can enter.

2. How does ZYMAR compare to older therapies like SPS?
ZYMAR offers fewer gastrointestinal side effects and better patient adherence, with rapid serum potassium reduction.

3. What are the main challenges in expanding ZYMAR’s market?
Patents expiry, competition from generics, reimbursement policies, and physician uptake.

4. Are there ongoing trials for new indications?
Yes, ongoing studies evaluate ZYMAR’s use in acute hyperkalemia and other conditions, which could expand its market.

5. How is ZYMAR priced relative to competitors?
It is priced at approximately $1,000 per month, higher than older therapies but justified by its safety and efficacy profile.

---

Sources
[1] MarketsandMarkets. Hyperkalemia Market Forecast. 2021-2028.
[2] FDA. Veltassa (patiromer) approval information. 2015.
[3] Vifor Pharma financial reports. 2022.